About us


Incuron, LLC Announces the Successful Completion of a Phase 1 Study of CBL0102

Incuron, a joint subsidiary of the Bioprocess Capital Ventures closed-end investment fund and Cleveland BioLabs, Inc. (NASDAQ:CBLI) announced the achievement of all objectives in a Phase 1 clinical trial of CBL0102 an orally administered small molecule. The study was performed in patients with advanced cancers for which no standard care exists or which had become resistant to conventional therapies. All patients had tumors involving the liver.



Incuron, LLC Announces Start of US Trial With CBL0137

Incuron, a joint subsidiary of the Bioprocess Capital Ventures closed-end investment fund and Cleveland BioLabs, Inc. (NASDAQ:CBLI),  announced that a multi-center, Phase 1, single agent, dose escalation trial evaluating intravenous administration of CBL0137 in patients with metastatic or unresectable advanced solid cancers and lymphomas is open for enrollment and that treatment of the first patient has been initiated.


With the support of the innovation center Skolkovo

About us

Incuron, LLC is a Russian Federation based joint venture founded in January 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures" (hereinafter "Fund"), and Cleveland BioLabs.

Incuron, LLC is developing an innovative pipeline of drugs to treat oncology and autoimmune disease for the global markets. Incuron's research and development operations include activities in both the Russian Federation and the U.S.


Scientific publications

  1. Gurova K., Hill J., Razorenova O., Chumakov P., Gudkov A. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism// Cancer Res., 2004, 64(6), 1951-8.
  2. Gurova K., Hill J., Guo C., Prokvolit A., Burdelya L., Samoylova E., Khodyakova A., Ganapathi R., Ganapathi M., Tararova N., Bosykh D., Lvovskiy D., Webb T., Stark G., Gudkov A. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kB dependent mechanism of p53 supression in tumors// PNAS, 2005, 102 (48): 17448-17453.
  3. Gurova K. New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents// Future Oncology, 2009, 5 (10), 1685.
  4. Neznanov N., Gorbachev A., Neznanova L., Komarov A., Gurova K., Gasparian A., Banerjee A., Almasan A., Fairchild R., Gudkov A. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications// Cell Cycle, 2009, 8(23) 3960-70.
  5. Guo C., Gasparian A.V., Zhuang Z., Bosykh D.A., Komar A.A., Gudkov A.V., Gurova K.V. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kB and p53 pathways// Oncogene, 2009, 28(8), 1151-61.
  6. Garcia H., Fleyshman D., Kolesnikova R., Safina A., Commane M., Paszkiewicz G., Omelian A., Morrison K., Gurova K.  Expression of FACT in mammalian tissues suggests its role in maintaining of undifferentiated state of cells// Oncotarget, 2011, 2(10), 783-96.
  7. Giulio F. Draetta and Ronald A. DePinho. Cancer Drug Discovery Faces the FACT// Sci Transl Med., 2011, 3(95), 95-97.
  8. Gasparian A. V., Burkhart C.A., Purmal A.A., Brodsky L., Pal M., Saranadasa M., Bosykh D.A., Commane M., Guryanova O.A., Pal S., Safina A., Sviridov S., Koman I.E., Veith J., Komar A.A., Gudkov A.V., Gurova K.V. Curaxins: Anticancer Compounds that Simultaneously Suppress NF-kB and Activate p53 by Targeting FACT// Sci Transl Med., 2011, 3 (95), 95ra74.
  9. Koman I.E., Commane M., Paszkiewicz G., Hoonjan B., Pal S., Safina A., Toshkov I., Purmal A.A., Wang D.,  Liu S., Morrison C., Gudkov A.V., Gurova K.V. // Targeting FACT Complex Suppresses Mammary Tumorigenesis in Her2/neu Transgenic Mice// Cancer Prev Res (Phila).,  2012, 5(8), 1025-35.
  10. Garcia H., Miecznikowski J., Safina A., Commane M., Ruusulehto A., Kilpinen S., Leach R., Attwood K., Li Y., Degan S., Omilian A., Guryanova O., Papantonopoulou O., Wang J., Buck M., Liu S., Morrison C., and Gurova K. // Facilitates Chromatin Transcription Complex is an ‘‘Accelerator’’ of Tumor Transformation and Potential Marker and Target of Aggressive Cancers // Cell Reports, 2013, 4, 1–15.